Press release
Alzther Industries in a Partnership to Develop Blood-based Test for Mild Cognitive Impairment, a Disorder Associated with Risk for Alzheimer’s disease
Seoul, 2016 - Alzther Industries a startup biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression and companion diagnostics for the early detection of Alzheimer’s disease, today announced a research agreement to collaborate initiative to develop a blood-based test using Alzther Industries’ peripheral gene expression profiling in patients with mild cognitive impairment, a disorder associated with risk for Alzheimer’s disease.
The study would be used in conjunction with PET imaging to identify a blood based gene expression signature in these patients. The PET imaging agent is currently in phase 3 development and is yet to be approved by a regulatory authority.
This research effort will combine expertise in data integration, informatics, genomics and imaging. Its goal will be to find a signature that may identify subjects at risk of Alzheimer’s at a very early disease stage.
“Alzther Industries has a global commitment to advancing clinical knowledge and providing innovations that may accelerate diagnosis of neurodegenerative diseases such as Alzheimer’s disease and transform patient management,” said Kim Seung-Yeon, General Manager, MI PET Segment.
“The collaboration we are announcing today is part of this effort to understand and identify Alzheimer’s disease in its very early stages. Finding a signature that identifies people at risk of developing the disease, may enable physicians to make more informed decisions about patient care.”
The ambition of the program is to increase the international success of the project, to enhance competitiveness and market success and through collaboration give access to new expertise, a global network, strategic partners and international markets.
Alzther Industries is a startup biotechnology company supported by various grants and private investors. The funds and our investors support projects with a high potential for future innovations. Alzther Industries is focused on diseases associated with protein misfolding. The company is currently developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease. Alzther Industries is focused on drug development until phase II clinical studies. The location of the company in Seoul enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.
Alzther Industries
Tower Palace Three, Tower G, 467 Dogok-dong, Seoul, South Korea
Oskar Jan Vijaya
pr@alzther.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzther Industries in a Partnership to Develop Blood-based Test for Mild Cognitive Impairment, a Disorder Associated with Risk for Alzheimer’s disease here
News-ID: 377750 • Views: …
More Releases from Alzther Industries
Alzther Industries Reports High 85% Accuracy for Blood-Based Diagnosis in Early …
Alzther Industries reported that their gene expression data contained information that can be used to classify PD with high average accuracy in peripheral blood
Alzther Industries (ISIN: KR7119857621) a startup biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease, today announced the initial findings from Alzther Industries prospective multicenter…
Alzther Industries Provides Update on Amyloid Imaging Study
Alzther Industries will evaluate to include up to 50 additional patients in the study and expects to report final study results during the fourth quarter this year
Seoul, 2016 - Alzther Industries a startup biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression and companion diagnostics for the early detection of Alzheimer’s disease, today reported intermediate results from an exploratory study that…
More Releases for Alzheimer’s
Europe Alzheimer’s Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure…
Media Advisory: Alzheimer’s Disease Resource Center, Inc. Presents 10th Annual …
Who: Mary Ann Malack-Ragona, Executive Director/Chief Executive Officer, Alzheimer’s Disease Resource Center, Inc. (ADRC)
Participating Walk for Alzheimer’s teams and individuals
Mickey B, Radio Personality, WGBB Radio and Master of Ceremonies
Ronald McDonald
The Liberty Bells, USO troupe
What: Alzheimer’s Disease Resource Center, Inc. (ADRC) is presenting its 10th Annual Old Bethpage Walk for Alzheimer’s & Mexican Fiesta. There will be an opening ceremony with Mickey B, Radio Personality, WGBB Radio, as the Master of…
Home Care Assistance Partners with the Alzheimer’s Association to Promote Earl …
(Palo Alto, CA – November 29, 2011) Home Care Assistance, North America’s leading provider of in-home care for seniors, announced today that, along with companies including Genworth, Starbucks, Intel and Pfizer, they are now a Champion Partner of the Alzheimer’s Early Detection Alliance (AEDA). The AEDA is a program renowned for raising Alzheimer’s awareness and promoting early detection of the disease. As a member of this important alliance, Home…
Alzheimer’s Association Long Island Announces Release of Latest Report on Alzh …
Alzheimer’s Association Long Island announced the release of the most recent report about Alzheimer’s disease. “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address” provides a look into the unrelenting challenges brought on by this disease by offering insights and perspectives from individuals across the country who participated in the Alzheimer’s Association’s public input process. The Association and over 70 of its chapters hosted 132 input sessions throughout…
Otava Alzheimer’s Disease Targeted Libraries
Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD. But there is no cure for AD and no treatment to reverse its progression, there are medicines available that can help treat symptoms in some people with this disease. Intensive scientific research around the world brings us closer to…
Alzheimer’s Association Long Island Presents Public Input Session for National …
On August 24, Alzheimer’s Association Long Island will hold a public input session to solicit views, comments and perspectives from stakeholders in the Alzheimer’s community to assist in the development of a successful National Alzheimer’s Plan. The recommendations and comments expressed during these input sessions, taking place across the country in August, will be collected and shared this fall with officials from the U.S. Department of Health and Human Services,…
